We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Show more
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis...
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Companyβs Phase 1a study of CDX-622 in...
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.01 | 4.27966101695 | 23.6 | 24.91 | 22.165 | 1033277 | 23.32964367 | CS |
4 | -0.27 | -1.08520900322 | 24.88 | 29.007 | 22.165 | 1077881 | 25.0432304 | CS |
12 | -2.345 | -8.69968465962 | 26.955 | 29.007 | 22.165 | 1065641 | 25.79982672 | CS |
26 | -12.61 | -33.8796346051 | 37.22 | 47 | 22.165 | 1029034 | 31.1338515 | CS |
52 | -15.47 | -38.5978043912 | 40.08 | 53.18 | 22.165 | 909884 | 35.2392517 | CS |
156 | -2.66 | -9.75430876421 | 27.27 | 53.18 | 19.85 | 700154 | 33.68249934 | CS |
260 | 22.28 | 956.223175966 | 2.33 | 57.2 | 1.5 | 769900 | 27.04159187 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions